Interní Med. 2012; 14(4): 173-176

How to prepare a patient treated with warfarin for surgery?

MUDr.Petr Kessler
Oddělení hematologie a transfuziologie, Nemocnice Pelhřimov, p.o.

The perioperative management of patients treated with warfarin should be based on the evaluation of the individual risk of thrombotic

complications and bleeding. The patients undergoing procedures associated with low risk of major bleeding (dental procedures, cataract

surgery, etc.) don‘t need any alteration of the anticoagulation; it’s however prudent to ascertain the INR seven days and one day prior to

the procedure to avoid the overanticoagulation. In patients undergoing all other invasive procedures the therapy with warfarin should

be stopped; bridging with low molecular weight heparin is required in some of them. The inherent risk of venous or arterial thromboembolism

is related to the underlying condition (reason for the anticoagulation). The risk of venous thromboembolism is in addition

increased by the surgery (postoperative risk). Preoperatively, the strategy is determined by the inherent risk of thrombosis. The therapy

with warfarin should be interrupted 5 days prior to the procedure. If the INR 1 day before surgery is ≥ 1.5, administering 1–2 mg of oral

vitamin K is suggested. In patients with low inherent risk no preoperative pharmacological thromboprophylaxis is needed. In patients

with high inherent risk (recent, idiopathic, recurrent, or paraneoplastic venous thromboembolism, mechanical heart valve prosthesis,

intermediate and high-risk atrial fibrillation) full dose of LMWH should be started immediately as the INR falls below 2.0. Therapy with

LMWH should be stopped 24 hours before surgery. In patients with intermediate inherent risk (provoked venous thromboembolism

older, than 6 weeks) prophylactic dose of LMWH should be started as the INR falls below 2.0; the last prophylactic dose should be administered

approximately 12 hours before surgery. The postoperative management is determined by the postoperative risk adjusted

according to the inherent risk and to the risk of bleeding. The prophylactic dose of LMWH is restarted usually 6–12 h post procedure,

when the haemostasis is secured. In patients with high inherent risk of venous thromboembolism and in patients with intermediate or

high risk of arterial thromboembolism the dose of LMWH should be increased to the therapeutic dose 48–72 hours after the end of the

surgery, if the haemostasis is secured. Warfarin is usually restarted in the evening of the day of procedure, or in the 1st postoperative day.

In patients requiring urgent surgery, the reversal of the effect of warfarin is necessary, if the INR is ≥ 1.5; the administration of low-dose

vitamin K (5 mg) orally or intravenously is recommended for them. For more immediate reversal of the anticoagulant effect treatment

with prothrombin concentrate is recommended (especially in patients requiring the surgery within ≤ 12 hours).

Keywords: warfarin, surgery, LMWH, vitamin K, bleeding

Published: April 23, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kessler P. How to prepare a patient treated with warfarin for surgery? Interní Med. 2012;14(4):173-176.
Download citation

References

  1. Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res. 2007; 120(1): 1-10. Go to original source... Go to PubMed...
  2. Muszkat M, Blotnik S, Elami A, et al. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clin Ther. 2007; 29(3): 427-437. Go to original source... Go to PubMed...
  3. Naganuma M, Shiga T, Nishikata K, et al. Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J Cardiovasc Pharmacol Ther. 2001; 6(4): 363-367. Go to original source... Go to PubMed...
  4. Gunes A, Coskun U, Boruban C, et al. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. Basic Clin Pharmacol Toxicol. 2006; 98(2): 197-200. Go to original source... Go to PubMed...
  5. Brewer AK. Continuing warfarin therapy does not increased risk of bleeding for patients undergoing minor dental procedures. Evid Based Dent. 2009; 10(2): 52. Go to original source... Go to PubMed...
  6. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy. American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 299-339. Go to original source...
  7. Patatanian E, Fugate SE. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. Ann Pharmacother. 2006; 40(12): 2205-2210. Go to original source... Go to PubMed...
  8. Sugden P, Siddiqui H. Continuing warfarin during cutaneous surgery. Surgeon 2008; 6(3): 148-150. Go to original source... Go to PubMed...
  9. Jamula E, Anderson J, Douketis JD. Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis. Thromb Res. 2009; 124(3): 292-299. Go to original source... Go to PubMed...
  10. Ono S, Fujishiro M, Hirano K, et al. Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. J Gastroenterol. 2009; 10. [Epub ahead of print]. Go to original source... Go to PubMed...
  11. Hui AJ, Wong RM, Ching JY, et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc. 2004; 59(1): 44-48. Go to original source... Go to PubMed...
  12. Ahmed I, Gertner E, Nelson WB, et al. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm. 2010; 7(6): 745-749. Go to original source... Go to PubMed...
  13. Ghanbari H, Feldman D, Schmidt M, et al. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol. 2010; 33(4): 400-406. Go to original source... Go to PubMed...
  14. Li HK, Chen FC, Rea RF, Asirvatham SJ, et al. No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure. Pacing Clin Electrophysiol. 2011; 34(7): 868-874. Go to original source... Go to PubMed...
  15. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 13, 285(22): 2864-2870. Go to original source... Go to PubMed...
  16. Gumulec J, Penka M, Bezděk R, et al. Prevence žilní tromboembolické nemoci: obecně platná pravidla. Vnitr Lek. 2006; 52(Suppl 1): 6-16. Go to PubMed...
  17. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 21, 110(12): 1658-1663. Go to original source... Go to PubMed...
  18. Woods K, Douketis JD, Kathirgamanathan K, et al. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J Thromb Thrombolysis. 2007; 24(2): 93-97. Go to original source... Go to PubMed...
  19. Adib T, Belli A, McCall J, et al. The use of inferior vena caval filters prior to major surgery in women with gynaecological cancer. BJOG. 2008; 115(7): 902-907. Go to original source... Go to PubMed...
  20. Lee A. VTE in patients with cancer-diagnosis, prevention, and treatment. Thromb Res. 2008; 123(Suppl 1): S50-54. Go to original source... Go to PubMed...
  21. Epstein NE. Intermittent pneumatic compression stocking prophylaxis against deep venous thrombosis in anterior cervical spinal surgery: a prospective efficacy study in 200 patients and literature review. Spine (Phila Pa 1976). 2005; 15, 30(22): 2538-2543. Go to original source... Go to PubMed...
  22. Barillari G, Pasca S. Practical use of intermittent pneumatic compression as thromboprophylaxis in neurosurgery. J Neurosurg Sci. 2009; 53(2): 45-48. Go to PubMed...
  23. Gumulec J, Kessler P, Procházka V, et al. Krvácivé komplikace antikoagulační léčby. Vnitr Lek. 2009; 55(3): 277-289. Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.